SURF-201 meets primary endpoints for the treatment of post-cataract pain, inflammation
SURF-201 (Surface Ophthalmics, Inc) met its primary endpoints of absence of inflammation at day 8 and day 15, according to top-line results from a Phase 2 trial.
In the trial, 91 patients who underwent cataract surgery received twice-daily dosing of SURF-201. The primary endpoints of complete clearance of anterior chamber cells were met at Day 8 (P = 0.01) and Day 15 (P = 0.001). Nearly 90% of patients were pain-free at day 15.
SURF-201 was found to be safe and well-tolerated.
“These results are, to me, extremely promising – showing impressive reduction in pain and inflammation – giving us strong Phase II evidence that SURF-201 has benefits for patients following ocular surgery,” said Richard Lindstrom, MD, in a press release. “With SURF-201, I’m excited to see betamethasone, a potent and safe corticosteroid popular in many countries, advance through clinical trials in the United States. I expect SURF-201 to be a significant new treatment option for the eyecare community, particularly in its unique unit-dose, preservative-free solution with the comforting Klarity vehicle.”
Read the full press release here.
